Longs Drug Stores Corporation (NYSE:LDG) is one of the leading drug store chains in North America, with annual sales per store of approximately $10 million. Longs operates 461 stores in California, Hawaii, Washington, Nevada, Colorado and Oregon. Longs focuses on meeting the specific health and well-being needs of the communities it serves with customer-oriented pharmacy services and convenient product offerings that include over-the-counter medications, photo and cosmetics

http://www.longs.com

    Total retail drug store sales     $353      $1,202     $2,421
    Increase (decrease) from
     comparable prior year period    (1.6)%       0.5%       1.7%

    Same-store sales increase
     (decrease):
        Pharmacy                     (2.7)%      (0.6)%      0.0%
        Front-end                    (4.5)%      (1.6)%     (0.1)%
        Total                        (3.5)%      (1.1)%     (0.1)%
Longs estimated that preliminary July pharmacy same-store sales were unfavorably impacted by approximately 275 to 300 basis points as a result of recent generic introductions being substituted for higher-priced brand name drugs. In addition, a reduction in cold, flu, and allergy prescriptions, primarily due to the impact of the switch of the prescription allergy medicine Zyrtec to over-the-counter status, had an unfavorable impact of approximately 75 to 100 basis points on pharmacy same-store sales. 
The Company also estimated that preliminary July pharmacy same-store sales were unfavorably impacted by approximately 200 to 250 basis points as a result of a shift in the fiscal calendar. As reported last month, the first three days of July were included in the fiscal month of June. Since there is typically an increase in the number of prescriptions filled in the first several days of a month, this calendar shift favorably impacted June pharmacy sales and unfavorably impacted July pharmacy sales

Longs Reports Preliminary April Retail Drug Store Sales
WALNUT CREEK, Calif., May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Longs Drug Stores Corporation (NYSE: LDG) today reported preliminary total retail drug store sales for the four-week and thirteen-week periods ended May 1, 2008. 
                                                     Periods ended May 1, 2008
                                                       Month          Quarter
    (Dollars in millions)                            (4 weeks)      (13 weeks)
    Total retail drug store sales                       $366         $1,220
    Increase from comparable prior year period           0.4%           2.9%
    Same-store sales increase (decrease):
      Pharmacy                                          (0.5)%          0.5%
      Front-end                                         (2.4)%          1.5%
      Total                                             (1.5)%          1.0%
Longs estimated that preliminary April front-end same-store sales were unfavorably impacted by approximately 450 to 475 basis points as a result of the three-week shift in Easter holiday sales. Easter occurred on March 23 this year versus April 8 last year. 

Longs estimated that preliminary April pharmacy same-store sales were unfavorably impacted by approximately 450 to 500 basis points as a result of recent generic introductions being substituted for higher-priced brand name drugs. In addition, the switch of the prescription allergy medicine Zyrtec to over-the-counter status and a mild conclusion to the cold and flu season versus last year had an unfavorable impact of approximately 125 to 150 basis points on pharmacy same-store sales

Longs Reports Preliminary January Retail Drug Store Sales From Continuing Operations
WALNUT CREEK, Calif., Feb 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Longs Drug Stores Corporation (NYSE: LDG) today reported preliminary total retail drug store sales from continuing operations. The fiscal year ended January 31, 2008, included 53 weeks of operations compared with 52 weeks in the prior year, with the additional week being the fifth week of January and the fourteenth week of the fourth quarter.
                                     Periods ended January 31, 2008
                                               Fourth          Year to
                                    Month      Quarter          Date
    (Dollars in Millions)         (5 weeks)  (14 weeks)      (53 weeks)

    Total retail drug store sales
     from continuing operations      $452       $1,344         $4,883
    Increase from prior year
     period                          28.8%         9.1%           4.9%

    Same-store sales are presented below on a comparable four-week basis for
the month of January, 13-week basis for the fourth quarter, and 52-week basis
for fiscal 2008
                                     Periods ended January 31, 2008
                                               Fourth          Year to
                                    Month      Quarter          Date

    (Dollars in Millions)         (4 weeks)  (13 weeks)      (52 weeks)

    Same-store sales increase
     (decrease):
     Pharmacy                         1.2%         0.7%           1.8%
     Front-end                        0.7%        (1.7%)          0.1%
     Total                            1.0%        (0.6%)          0.9%
As announced on February 28, 2007, the results of operations associated with the 23 stores for which the Company has announced plans to close in Colorado, Oregon and Washington are classified as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144 (FAS 144), "Accounting for the Impairment or Disposal of Long-Lived Assets." In accordance with FAS 144, the sales from stores classified as discontinued operations are not included in the preliminary sales from continuing operations reported today. 

Longs Drug Stores Corporation Reports 45% Increase in Third Quarter Income From Continuing Operations
WALNUT CREEK, Calif., Nov 14, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Longs Drug Stores Corporation (NYSE: LDG) today reported preliminary income from continuing operations for the third quarter ended October 25, 2007 of $19.3 million, or $0.51 per diluted share, an increase of 45 percent compared with income from continuing operations for the third quarter ended October 26, 2006 of $13.3 million, or $0.35 per diluted share.
Total revenues of $1.24 billion for the thirteen weeks ended October 25, 2007 were 3.3 percent higher than the $1.20 billion reported in the comparable period last year. Total retail drug store sales increased 3.1 percent and total pharmacy benefit services revenues increased 6.3 percent compared with the same period last year.
Commenting on the quarter, Chairman, President and Chief Executive Officer Warren F. Bryant said, "We are encouraged by our financial results for the quarter and pleased with the performance of both the retail and pharmacy benefit services segments. We are improving the profitability of our retail segment and better aligning our stores with our longer term goals while we continue to pursue new business opportunities at RxAmerica."
During the third quarter, Longs opened 13 stores and remodeled 25 stores. The Company is estimating capital expenditures for the full year of Fiscal 2008 to be in the range of $170 million to $200 million. Longs plans to open or relocate approximately 30 to 35 stores and remodel up to 46 stores in Fiscal 2008.
The Company also announced its expansion plans to open or relocate 20 to 30 stores and remodel up to 40 stores next year and estimated capital expenditures for Fiscal 2009 in the range of $150 million to $200 million. Over the next five years, the Company plans to grow its number of stores at a compound annual growth rate of 7 percent.
During the third quarter, Longs Drugs repurchased 419,000 shares of common stock at an average price of $50.84 per share for a total investment of $21.3 million. Approximately $25 million remains under previous Board authorization and yesterday, the Board of Directors authorized the repurchase of up to an additional $200 million of the Company's common stock during the period extending through February 28, 2011.
THIRD QUARTER
Income
Income from continuing operations for the thirteen weeks ended October 25, 2007, was $19.3 million, or $0.51 per diluted share, compared with income from continuing operations for the thirteen weeks ended October 26, 2006 of $13.3 million, or $0.35 per diluted share.
Revenues
Total revenues of $1.24 billion for the thirteen weeks ended October 25, 2007 were 3.3 percent higher than the $1.20 billion reported in the comparable period last year. Total retail drug store sales were $1.16 billion, a 3.1 percent increase from $1.12 billion in the comparable period last year. Same-store sales increased 1.4 percent with pharmacy same-store sales increasing 2.0 percent and front-end same-store sales increasing 0.8 percent. Pharmacy sales were 52.6 percent of total drug store sales during the period, compared with 51.9 percent a year ago.
Pharmacy benefit services generated a 6.3 percent increase in revenues during the third quarter to $79.7 million compared with $75.0 million reported last year. Pharmacy benefit management services generated revenues of $19.1 million compared with third quarter revenues last year of $9.7 million and the prescription drug plans for Medicare beneficiaries generated revenues of $60.7 million compared with $65.3 million a year ago